

September 21, 2023

To,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.

Ref: Scrip Name: GLENMARK

Kind attn: Binoy Yohannan, Associate Vice President - Surveillance

Dear Sir,

Sub: Clarification/Confirmation on news item appearing in “Media/Publication”

We refer to your letter no. NSE/CM/Surveillance/13410 dated September 21, 2023.

In this regard, we request you to refer to disclosures dated September 21, 2023 pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, in relation to (i) outcome of the board meeting held on September 21, 2023; (ii) the press release titled "Glenmark Pharma announces proposed divestment of majority stake in Glenmark Life Sciences"; and (iii) the investor presentation titled "Glenmark Pharma announces proposed divestment of majority stake in Glenmark Life Sciences", uploaded on the websites of the NSE and the BSE earlier today.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

Harish Kuber
Company Secretary & Compliance Officer

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com